[
  {
    "ts": null,
    "headline": "Goldman Sachs Downgrades Pfizer (PFE)",
    "summary": "Goldman Sachs Downgrades Pfizer (PFE)",
    "url": "https://finnhub.io/api/news?id=69319f571a407055b998045f45950ad92deb72c3798bea94cb364f019e1516e1",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744148364,
      "headline": "Goldman Sachs Downgrades Pfizer (PFE)",
      "id": 133799486,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=69319f571a407055b998045f45950ad92deb72c3798bea94cb364f019e1516e1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock’s Fall to ’97 Level Lifts Yield Near 8%. Dividend Looks Safe.",
    "summary": "Pfizer  stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a  UBS  analyst ahead of the company’s quarterly earnings on April 29.  Pfizer shares declined 3.5% to $21.84 after hitting a new 52-week low of $21.44.  All that has resulted in a generation of frustration for investors in what once was the top drug company in the world by market value.",
    "url": "https://finnhub.io/api/news?id=1e7f38b53254866cf680ee71b2d75662ab7cb331089f5238d295915e0fe952e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744147560,
      "headline": "Pfizer Stock’s Fall to ’97 Level Lifts Yield Near 8%. Dividend Looks Safe.",
      "id": 133823648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer  stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a  UBS  analyst ahead of the company’s quarterly earnings on April 29.  Pfizer shares declined 3.5% to $21.84 after hitting a new 52-week low of $21.44.  All that has resulted in a generation of frustration for investors in what once was the top drug company in the world by market value.",
      "url": "https://finnhub.io/api/news?id=1e7f38b53254866cf680ee71b2d75662ab7cb331089f5238d295915e0fe952e4"
    }
  },
  {
    "ts": null,
    "headline": "Biggest Jumps In Dividend Yields",
    "summary": "Currently, the S&P 500's dividend yield of 1.64% is the highest it has been since November 2023. Click to read.",
    "url": "https://finnhub.io/api/news?id=7bf69e6dab6d5a0f5423e55208cbb081e82a7257224765d676fdc7e0195bf2f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744137900,
      "headline": "Biggest Jumps In Dividend Yields",
      "id": 133804454,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358927461/image_1358927461.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Currently, the S&P 500's dividend yield of 1.64% is the highest it has been since November 2023. Click to read.",
      "url": "https://finnhub.io/api/news?id=7bf69e6dab6d5a0f5423e55208cbb081e82a7257224765d676fdc7e0195bf2f0"
    }
  },
  {
    "ts": null,
    "headline": "Building A $100,000 Dividend Portfolio: Enhancing SCHD With April's Top High-Yield Picks",
    "summary": "Enhance your dividend strategy with April 2025's top high-yield picks. Click here to learn how to boost SCHD income and optimize your portfolio's risk-reward balance.",
    "url": "https://finnhub.io/api/news?id=306a992842aae5d6149230ab59ff4971d480f95ddae7c596fbb018078e5d5dd3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744135200,
      "headline": "Building A $100,000 Dividend Portfolio: Enhancing SCHD With April's Top High-Yield Picks",
      "id": 133801761,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159094952/image_2159094952.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Enhance your dividend strategy with April 2025's top high-yield picks. Click here to learn how to boost SCHD income and optimize your portfolio's risk-reward balance.",
      "url": "https://finnhub.io/api/news?id=306a992842aae5d6149230ab59ff4971d480f95ddae7c596fbb018078e5d5dd3"
    }
  },
  {
    "ts": null,
    "headline": "Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie",
    "summary": "Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks",
    "url": "https://finnhub.io/api/news?id=bc94276900cad2ebcc0b80e6d2292450595274f18897df2b28b0da16be1a544f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744135093,
      "headline": "Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie",
      "id": 133811148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks",
      "url": "https://finnhub.io/api/news?id=bc94276900cad2ebcc0b80e6d2292450595274f18897df2b28b0da16be1a544f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a86e3fbf21174bb5efdc11e72d0f5f977c8763d60b8798edc7a34d242fbb91e0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744130160,
      "headline": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "id": 133832088,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a86e3fbf21174bb5efdc11e72d0f5f977c8763d60b8798edc7a34d242fbb91e0"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (PFE) Stock Undervalued Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=8378d65eb2f4b25829559eb1c25841ffec2b32e9a513214c979bcbe1bea744a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744119610,
      "headline": "Is Pfizer (PFE) Stock Undervalued Right Now?",
      "id": 133823652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=8378d65eb2f4b25829559eb1c25841ffec2b32e9a513214c979bcbe1bea744a8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
    "summary": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
    "url": "https://finnhub.io/api/news?id=3770741deb59d49197223c629edb50225ba3a0352071fea69192947755159d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744118100,
      "headline": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
      "id": 133823361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
      "url": "https://finnhub.io/api/news?id=3770741deb59d49197223c629edb50225ba3a0352071fea69192947755159d36"
    }
  },
  {
    "ts": null,
    "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
    "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
    "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744117697,
      "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
      "id": 133820740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
      "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3"
    }
  },
  {
    "ts": null,
    "headline": "Down 62%, Should You Buy the Dip on Pfizer?",
    "summary": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
    "url": "https://finnhub.io/api/news?id=e5cc87377f87af7a2b88f5d45744cc1f1fed442655508b90f9fb525ace7b3a29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744101600,
      "headline": "Down 62%, Should You Buy the Dip on Pfizer?",
      "id": 133823657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
      "url": "https://finnhub.io/api/news?id=e5cc87377f87af7a2b88f5d45744cc1f1fed442655508b90f9fb525ace7b3a29"
    }
  }
]